Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

CIBC Sees Strength in QLT Inc.


CIBC World reiterated its strong buy rating on QLT Inc. (QLTI) shares.

Analyst Matthew Geller says the pharmaceutical announced positive 24-month results in its Phase IIIb trial for Visudyne in patients with an occult form of wet age-related macular degeneration and in patients with pathological myopia. He says the data could triple the market for the drug.

Geller notes that management will meet soon with the FDA and the agency's European equivalent with regard to expanding drug labels to include occult disease. Geller says Visudyne will likely receive a 6-month priority review in the U.S. He believes the news will help calm investors' concerns about the size of the Visudyne market and will lift QLT's stock price.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus